Assesses the evidence that three marketed gene exp

Home > Diane Publishing Books >

Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes

Our Price: $45.00

By Luigi Marchionni (au)
Year: 2008
Pages: 221
Binding Paperback

Product Code: 1437911048

Description

Assesses the evidence that three marketed gene expression-based assays improve prognostic accuracy, treatment choice, and health outcomes in women diagnosed with early stage breast cancer. Three gene expression assays were evaluated; Oncotype DX™, MammaPrint® and the Breast Cancer Profiling (BCP or H/I ratio) test, and for gene expression signatures underlying the assays. They sought evidence on: analytic performance of tests; clinical validity; clinical utility; harms; and impact on clinical decision making and health care costs. Conclusions: Oncotype DX is furthest along the validation pathway, with retrospective evidence that it predicts distant spread and chemotherapy benefit to a clinically relevant extent over standard predictors. Illus.

Share your knowledge of this product with other customers... Be the first to write a review